Armata Pharmaceuticals, Inc. 8-K

What Happened

• On January 13, 2026, Armata Pharmaceuticals, Inc. announced via press release (furnished on Form 8‑K) that it received an End-of-Phase 2 written response from the U.S. Food and Drug Administration and plans to advance its intravenously‑administered Staphylococcus aureus (S. aureus) bacteriophage candidate, AP‑SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia. The announcement was made under Regulation FD disclosure.

Key Details

• Filing date: January 13, 2026 (Current Report on Form 8‑K, Item 7.01).
• Regulatory milestone: FDA End-of-Phase 2 written response concluded.
• Next step: Company plans to initiate a Phase 3 study of AP‑SA02 for complicated S. aureus bacteremia.
• Disclosure: Press release furnished as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• Advancing from Phase 2 to Phase 3 is a major clinical development and a potential value inflection point for a biotech company; it signals the program will test efficacy and safety on a larger, pivotal scale.
• The filing does not provide Phase 3 start dates, trial design details, or financial information — investors should look for follow-up disclosures for timing, study size, endpoints, and funding plans.
• This is a regulatory progress update (not a financial report); watch for additional SEC filings and company releases for operational or financial impacts.